

## **Part VI: Summary of the risk management plan**

### Summary of risk management plan for

#### Clinelin 10 mg/g + 50 mg/g gel (clindamycin + anhydrous benzoyl peroxide)

This is a summary of the risk management plan (RMP) for Clinelin. The RMP details important risks of Clinelin, how these risks can be minimised, and how more information will be obtained about Clinelin's risks and uncertainties (missing information).

Summary of product characteristics (SmPC) of Clinelin and its package leaflet give essential information to healthcare professionals and patients on how Clinelin should be used.

Important new concerns or changes to the current ones will be included in updates of Clinelin's RMP.

### **I. The medicine and what it is used for**

Clinelin is authorised for the topical treatment of mild to moderate acne vulgaris, particularly inflammatory lesions, in adults and adolescents aged 12 years and above. It contains clindamycin and anhydrous benzoyl peroxide as active substances and is administered to the skin.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Clinelin, together with measures to minimise such risks and the proposed studies for learning more about Clinelin's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR so that immediate action can

be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

### **II.A List of important risks and missing information**

Important risks of Clinelin are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Clinelin. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	none
Important potential risks	none
Missing information	none

### **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### **II.C Post-authorisation development plan**

#### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Clinelin.

#### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Clinelin.